Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05691504 · ClinicalTrials.gov registry record · Phase 1

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

A Phase 1 study of Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 1
Development phase
42
Enrollment target
6
Study locations

NCT05691504: Recruiting Phase 1 study of Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma, sponsored by National Cancer Institute (NCI).

NCT05691504 is a Phase 1 study of Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants, below the 228-participant average among 35 other Recurrent Fallopian Tube Carcinoma trials with a reported enrollment target (82% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05691504, a Phase 1 study of Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
6
Study locations

Study Summary

This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving APG-1252 in combination with cobimetinib may shrink or stabilize tumor in patients with recurrent ovarian and endometrial cancers.

Primary Outcome

Will be identified using a Bayesian optimal interval design.

Conditions Studied

Recurrent Fallopian Tube Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Endometrial Carcinoma Advanced Endometrial Carcinoma Recurrent Platinum-Resistant Ovarian Carcinoma Metastatic Endometrial Carcinoma Metastatic Fallopian Tube Carcinoma Metastatic Primary Peritoneal Carcinoma Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 Metastatic Platinum-Resistant Ovarian Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy Procedure
  • PROCEDURE Echocardiography Test
  • DRUG Cobimetinib

Study Locations (6)

Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
  • National Cancer Institute Developmental Therapeutics Clinic - Bethesda
  • National Institutes of Health Clinical Center - Bethesda

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2023-09-14
Est. Completion 2027-02-01
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What NCT05691504 shows while recruiting

NCT05691504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 228-participant average among 35 other Recurrent Fallopian Tube Carcinoma trials with a reported enrollment target (82% lower).

The record links to 10 conditions, with Recurrent Fallopian Tube Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05691504 lists 6 locations in 4 states (Maryland, Georgia, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT05691504 about?

NCT05691504 is a clinical study titled "Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers". This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of pr...

What is the current status of trial NCT05691504?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-09-14. Estimated completion is 2027-02-01.

What conditions does trial NCT05691504 study?

This clinical trial studies the following conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Advanced Endometrial Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma.

What interventions are being tested in trial NCT05691504?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Echocardiography Test (PROCEDURE), Cobimetinib (DRUG).

Who is sponsoring clinical trial NCT05691504?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05691504 being conducted?

This trial has 6 study locations across Georgia, Maryland, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Fallopian Tube Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05691504's enrollment target sits among peer trials

42 21st of 35 higher than 15 of 35 other Recurrent Fallopian Tube Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Recurrent Fallopian Tube Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05691504

Source: ClinicalTrials.gov NCT05691504, the US trial registry maintained by the National Library of Medicine. NCT05691504 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.